These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29697151)

  • 1. An updated overview with simple and practical approach for developing in vitro-in vivo correlation.
    Jacob S; Nair AB
    Drug Dev Res; 2018 May; 79(3):97-110. PubMed ID: 29697151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.
    Costello C; Rossenu S; Vermeulen A; Cleton A; Dunne A
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):519-39. PubMed ID: 21735135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro-in vivo correlation strategy applied to an immediate-release solid oral dosage form with a biopharmaceutical classification system IV compound case study.
    Bredael GM; Bowers N; Boulineau F; Hahn D
    J Pharm Sci; 2014 Jul; 103(7):2125-2130. PubMed ID: 24890761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
    Kakhi M; Marroum P; Chittenden J
    Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the prediction accuracy of two IVIVC modelling techniques.
    Gaynor C; Dunne A; Davis J
    J Pharm Sci; 2008 Aug; 97(8):3422-32. PubMed ID: 17990312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.
    Modi NB; Lam A; Lindemulder E; Wang B; Gupta SK
    Biopharm Drug Dispos; 2000 Nov; 21(8):321-6. PubMed ID: 11514951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.
    Margolskee A; Darwich AS; Galetin A; Rostami-Hodjegan A; Aarons L
    AAPS J; 2016 Mar; 18(2):321-32. PubMed ID: 26667356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester.
    Taha NF; Emara LH
    AAPS PharmSciTech; 2022 Jul; 23(6):202. PubMed ID: 35882726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
    Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
    AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Experience with In Vivo In Vitro Correlations (IVIVC) in New Drug Applications.
    Suarez-Sharp S; Li M; Duan J; Shah H; Seo P
    AAPS J; 2016 Nov; 18(6):1379-1390. PubMed ID: 27480319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
    Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
    J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
    Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
    J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.